Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Postinduction molecular MRD identifies patients with NPM1 AML who benefit from allogeneic transplant in first remission
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 143, Iss. 19, pp. 1931-1936
Closed Access | Times Cited: 28

Showing 1-25 of 28 citing articles:

Molecular, clinical, and therapeutic determinants of outcome in NPM1-mutated AML
Jad Othman, Nicola Potter, Adam Ivey, et al.
Blood (2024) Vol. 144, Iss. 7, pp. 714-728
Closed Access | Times Cited: 23
Impact of myelodysplasia‐related and additional gene mutations in intensively treated patients with NPM1‐mutated AML
Sibylle Cocciardi, Maral Saadati, Nina Weiß, et al.
HemaSphere (2025) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Current status and research directions in acute myeloid leukemia
Hagop M. Kantarjian, Gautam Borthakur, Naval Daver, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 10
Acute Myeloid Leukemia: 2025 Update on Diagnosis, Risk‐Stratification, and Management
Shai Shimony, Maximilian Stahl, Richard M. Stone
American Journal of Hematology (2025)
Open Access | Times Cited: 1
Challenges in Consensus Regarding the Treatment of Myeloid Malignancies
Hetty E. Carraway
(2025)
Closed Access
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group
Guadalupe Oñate, Ana Garrido, Montserrat Arnán, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access
Diagnosis and treatment of AML in the context of WHO and ICC 2022 classifications: Divergent nomenclature converges on common therapies
Uwe Platzbecker, Richard A. Larson, Sandeep Gurbuxani
HemaSphere (2025) Vol. 9, Iss. 2
Open Access
Biology and Management of Acute Myeloid Leukemia With Mutated NPM1
Evan C. Chen, Shai Shimony, Marlise R. Luskin, et al.
American Journal of Hematology (2025)
Closed Access
Significance of Measurable Residual Disease in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia
Margery Gang, Megan Othus, Roland B. Walter
Cells (2025) Vol. 14, Iss. 4, pp. 290-290
Open Access
Frontline Therapy of AML in the Fit and Younger Population—Incorporating Molecularly Targeted Agents
Keith W. Pratz, Harry P. Erba
American Journal of Hematology (2025) Vol. 100, Iss. S2, pp. 16-22
Open Access
Intensive post-remission therapy does not decrease relapse after allotransplants for acute myeloid leukaemia in 1st remission and should not be given
Eduardo Rodríguez‐Arbolí, GL Phillips, Timothy S. Pardee, et al.
Leukemia (2025)
Closed Access
Perspectives on Current Challenges and Emerging Approaches for the Management of CH, MDS, and AML From the 1st Bridging the Gaps in Leukemia, Lymphoma, and Multiple Myeloma Conference
Hetty E. Carraway, Andrew M. Brunner, Catherine Lai, et al.
Clinical Lymphoma Myeloma & Leukemia (2025)
Closed Access
Therapeutic horizon of acute myeloid leukemia: Success, optimism, and challenges
Jayastu Senapati, Tapan M. Kadia, Naval Daver, et al.
Cancer (2025) Vol. 131, Iss. 7
Closed Access
Effect of NPM1 Mutation Subtype and Co‐Mutation Patterns on the Outcomes of Acute Myeloid Leukemia
Kittika Poonsombudlert, Ratdanai Yodsuwan, Sarah L. Mott, et al.
European Journal Of Haematology (2025)
Open Access
Stem cell transplantation indications for patients with acute leukemia determined by measurable residual disease: what we know and what we do not know
Xiaosu Zhao, Xiaotong Chen, Ying‐Jun Chang
Blood Science (2025) Vol. 7, Iss. 2, pp. e00229-e00229
Open Access
Prognostic significance of deep sequencing for analysis of measurable residual disease in acute myeloid leukemia with NPM1 mutation
Sofie Johansson Alm, Gustav Orrsjö, Giti Shah Barkhordar, et al.
Leukemia & lymphoma/Leukemia and lymphoma (2025), pp. 1-11
Open Access
Acute myeloid leukemia management and research in 2025
Hagop M. Kantarjian, Courtney D. DiNardo, Tapan M. Kadia, et al.
CA A Cancer Journal for Clinicians (2024)
Open Access | Times Cited: 3
Transplant in AML: just follow the NPM1 guide!
Christian Récher
Blood (2024) Vol. 143, Iss. 19, pp. 1881-1882
Open Access | Times Cited: 2
Real-Life Management of FLT3-Mutated AML: Single-Centre Experience over 24 Years
Saveria Capria, Silvia Maria Trisolini, Lorenzo Torrieri, et al.
Cancers (2024) Vol. 16, Iss. 16, pp. 2864-2864
Open Access | Times Cited: 2
Measurable residual disease monitoring in AML: Prospects for therapeutic decision‐making and new drug development
Nicholas J. Short, Richard Dillon
American Journal of Hematology (2024)
Closed Access | Times Cited: 2
Pre-emptive therapeutic decisions based on measurable residual disease status in acute myeloid leukemia: ready for prime time?
Firas El Chaer, Anthony J. Perissinotti, Sanam Loghavi, et al.
Leukemia (2024)
Closed Access | Times Cited: 2
Measurable residual disease (MRD)-testing in haematological cancers: A giant leap forward or sideways?
Qiujin Shen, Xiaowen Gong, Yahui Feng, et al.
Blood Reviews (2024) Vol. 68, pp. 101226-101226
Open Access | Times Cited: 1
Targeting Menin in Acute Myeloid Leukemia: Therapeutic Advances and Future Directions
Sandhya Dhiman, Vikram Dhillon, Suresh Kumar Balasubramanian
Cancers (2024) Vol. 16, Iss. 22, pp. 3743-3743
Open Access | Times Cited: 1
Dynamics of measurable residual disease for risk stratification and guiding allogeneic transplant in acute myeloid leukaemia patients with myelodysplasia‐related mutations in first remission
Ling Jiang, Jiaying Cheng, Junya Sun, et al.
British Journal of Haematology (2024)
Open Access | Times Cited: 1
Post‐Relapse Outcomes of Older Patients With NPM1‐Mutated AML Are Favorable With Allo Transplant in Second Remission
Avraham Frisch, Chezi Ganzel, Yishai Ofran, et al.
European Journal Of Haematology (2024)
Open Access | Times Cited: 1
Page 1 - Next Page

Scroll to top